Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: June 29, 2022

MOTEGRITY Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Motegrity patents expire, and what generic alternatives are available?

Motegrity is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this compound. Additional details are available on the prucalopride succinate profile page.

Summary for MOTEGRITY
Drug patent expirations by year for MOTEGRITY
Drug Prices for MOTEGRITY

See drug prices for MOTEGRITY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for MOTEGRITY
Generic Entry Date for MOTEGRITY*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MOTEGRITY

US Patents and Regulatory Information for MOTEGRITY

MOTEGRITY is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOTEGRITY is See Plans and Pricing.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting MOTEGRITY

Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa MOTEGRITY prucalopride succinate TABLET;ORAL 210166-001 Dec 14, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Takeda Pharms Usa MOTEGRITY prucalopride succinate TABLET;ORAL 210166-002 Dec 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.